Vault-13

DEERFIELD MANAGEMENT COMPANY, L.P.

New York, NY · CIK 1009258 · 13F filing filed 2022-05-16

SEC-registered investment adviser since 2012 · limited partnership

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 86
Parsippany, NJUnited States United States3

US visa salary filings

Job titleFilingsMedianRange
AnalystNew York, NY 2 $140,000
Data EngineerNew York, NY 1 $210,000
Senior Director, Business IntelligenceNew York, NY 1 $195,000
Director, Business IntelligenceNew York, NY 1 $180,000
Market Research AssociateNew York, NY 1 $80,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Deerfield Management Company, L.P..

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$4.5bn reported value -5.9% vs Q4 2021
121positions
41.9%in top 10
15 new 17 added 16 reduced 19 sold out vs Q4 2021

Options: 1 call positions ($2.6m notional), 0 put positions (— notional) – listed below, not included above.

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q1 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 GLAUKOS CORP NOTE 2.750% 6/1 · principal GKOS 2.75 06.15.27 · principal GKOS 2.75 06.15.27 269,897,000 $358.8m8.03% 8.03% AddedPrincipal held: Q2 2021 90.0m, Q3 2021 108.0m, Q4 2021 204.7m, Q1 2022 269.9m +65.2m +65,197,000 31.9%
2 NUVALENT INC COM COM 19,341,024 $268.6m6.01% 6.01% UnchangedShares held: Q2 2021 0, Q3 2021 19.3m, Q4 2021 19.3m, Q1 2022 19.3m
3 VIATRIS INC COM VTRS VTRS 20,673,700 $224.9m5.03% 5.03% ReducedShares held: Q2 2021 18.8m, Q3 2021 18.8m, Q4 2021 20.8m, Q1 2022 20.7m -100.3k -100,300 -0.5%
4 ADAPTHEALTH CORP COMMON STOCK AHCO AHCO 11,650,072 $186.8m4.18% 4.18% AddedShares held: Q2 2021 7.4m, Q3 2021 8.1m, Q4 2021 10.2m, Q1 2022 11.7m +1.4m +1,424,627 13.9%
5 INVITAE CORP NOTE 2.000% 9/0 · principal NVTA 2 09.01.24 · principal NVTA 2 09.01.24 206,873,000 $169.8m3.80% 3.80% AddedPrincipal held: Q2 2021 163.4m, Q3 2021 163.4m, Q4 2021 163.4m, Q1 2022 206.9m +43.5m +43,488,000 26.6%
6 NEUROCRINE BIOSCIENCES INC COM NBIX NBIX 1,657,800 $155.4m3.48% 3.48% AddedShares held: Q2 2021 725.0k, Q3 2021 1.1m, Q4 2021 1.4m, Q1 2022 1.7m +279.9k +279,855 20.3%
7 AERIE PHARMACEUTICALS INC NOTE 1.500%10/0 · principal AERI 1.5 10.01.24 · principal AERI 1.5 10.01.24 157,390,000 $141.9m3.17% 3.17% UnchangedPrincipal held: Q2 2021 157.4m, Q3 2021 157.4m, Q4 2021 157.4m, Q1 2022 157.4m
8 ENVISTA HOLDINGS CORPORATION NOTE 2.375% 6/0 · principal NVST 2.375 06.01.25 · principal NVST 2.375 06.01.25 52,500,000 $123.9m2.77% 2.77% UnchangedPrincipal held: Q2 2021 52.5m, Q3 2021 52.5m, Q4 2021 52.5m, Q1 2022 52.5m
9 CAREMAX INC COM CL A COM CL A 15,861,090 $121.8m2.72% 2.72% ReducedShares held: Q2 2021 16.8m, Q3 2021 16.8m, Q4 2021 16.8m, Q1 2022 15.9m -917.7k -917,660 -5.5%
10 NATERA INC NOTE 2.250% 5/0 · principal NTRA 2.25 05.01.27 · principal NTRA 2.25 05.01.27 90,638,000 $120.2m2.69% 2.69% AddedPrincipal held: Q2 2021 45.0m, Q3 2021 45.0m, Q4 2021 45.0m, Q1 2022 90.6m +45.6m +45,638,000 101.4%
11 SAREPTA THERAPEUTICS INC DBCV 1.500%11/1 SRPT 1.5 11.15.24 SRPT 1.5 11.15.24 88,657,000 $116.1m2.60% 2.60% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 88.7m
12 PACIRA BIOSCIENCES INC NOTE 0.750% 8/0 · principal PCRX 0.75 08.01.25 · principal PCRX 0.75 08.01.25 81,600,000 $100.9m2.26% 2.26% UnchangedPrincipal held: Q2 2021 0, Q3 2021 81.6m, Q4 2021 81.6m, Q1 2022 81.6m
13 NUVASIVE INC NOTE 1.000% 6/0 · principal GMED 1 06.01.23 · principal GMED 1 06.01.23 96,966,000 $96.4m2.16% 2.16% UnchangedPrincipal held: Q2 2021 97.0m, Q3 2021 97.0m, Q4 2021 97.0m, Q1 2022 97.0m
14 PULMONX CORP COM LUNG LUNG 3,695,341 $91.7m2.05% 2.05% AddedShares held: Q2 2021 1.8m, Q3 2021 2.0m, Q4 2021 2.4m, Q1 2022 3.7m +1.3m +1,328,474 56.1%
15 SILK RD MED INC COM SILK SILK 2,153,712 $88.9m1.99% 1.99% AddedShares held: Q2 2021 1.1m, Q3 2021 990.3k, Q4 2021 1.5m, Q1 2022 2.2m +636.5k +636,531 42.0%
16 IVERIC BIO INC COM OPHT OPHT 4,891,996 $82.3m1.84% 1.84% AddedShares held: Q2 2021 5.8m, Q3 2021 4.9m, Q4 2021 4.8m, Q1 2022 4.9m +130.9k +130,858 2.8%
17 APELLIS PHARMACEUTICALS INC NOTE 3.500% 9/1 · principal APLS 3.5 09.15.26 · principal APLS 3.5 09.15.26 51,885,000 $81.7m1.83% 1.83% AddedPrincipal held: Q2 2021 41.8m, Q3 2021 28.8m, Q4 2021 28.8m, Q1 2022 51.9m +23.1m +23,060,000 80.0%
18 TABULA RASA HEALTHCARE INC NOTE 1.750% 2/1 · principal TRHC 1.75 02.15.26 · principal TRHC 1.75 02.15.26 107,816,000 $79.7m1.78% 1.78% AddedPrincipal held: Q2 2021 45.0m, Q3 2021 45.0m, Q4 2021 97.8m, Q1 2022 107.8m +10.0m +10,000,000 10.2%
19 INSULET CORP NOTE 0.375% 9/0 · principal PODD 0.375 09.01.26 · principal PODD 0.375 09.01.26 57,581,000 $76.2m1.71% 1.71% UnchangedPrincipal held: Q2 2021 57.6m, Q3 2021 57.6m, Q4 2021 57.6m, Q1 2022 57.6m
20 NUVASIVE INC NOTE 0.375% 3/1 · principal GMED 0.375 03.15.25 · principal GMED 0.375 03.15.25 80,000,000 $76.1m1.70% 1.70% AddedPrincipal held: Q2 2021 40.0m, Q3 2021 55.8m, Q4 2021 77.9m, Q1 2022 80.0m +2.1m +2,141,000 2.8%
21 INSMED INC NOTE 1.750% 1/1 · principal INSM 1.75 01.15.25 · principal INSM 1.75 01.15.25 75,000,000 $74.9m1.68% 1.68% AddedPrincipal held: Q2 2021 50.0m, Q3 2021 50.0m, Q4 2021 50.0m, Q1 2022 75.0m +25.0m +25,000,000 50.0%
22 MIRUM PHARMACEUTICALS INC COM MIRM MIRM 3,282,912 $72.3m1.62% 1.62% UnchangedShares held: Q2 2021 3.4m, Q3 2021 3.3m, Q4 2021 3.3m, Q1 2022 3.3m
23 KURA ONCOLOGY INC COM KURA KURA 4,416,361 $71.0m1.59% 1.59% AddedShares held: Q2 2021 1.8m, Q3 2021 2.3m, Q4 2021 3.5m, Q1 2022 4.4m +902.6k +902,605 25.7%
24 NEVRO CORP NOTE 2.750% 4/0 · principal NVRO 2.75 04.01.25 · principal NVRO 2.75 04.01.25 61,000,000 $65.4m1.46% 1.46% UnchangedPrincipal held: Q2 2021 12.0m, Q3 2021 26.0m, Q4 2021 61.0m, Q1 2022 61.0m
25 ORGANOGENESIS HLDGS INC COM ORGO ORGO 8,456,876 $64.4m1.44% 1.44% UnchangedShares held: Q2 2021 7.2m, Q3 2021 7.5m, Q4 2021 8.5m, Q1 2022 8.5m
26 INTERCEPT PHARMACEUTICALS IN NOTE 3.250% 7/0 · principal ICPT 3.25 07.01.23 · principal ICPT 3.25 07.01.23 57,791,000 $53.0m1.19% 1.19% UnchangedPrincipal held: Q2 2021 57.8m, Q3 2021 57.8m, Q4 2021 57.8m, Q1 2022 57.8m
27 DECIPHERA PHARMACEUTICALS IN COM DCPH DCPH 5,580,456 $51.7m1.16% 1.16% UnchangedShares held: Q2 2021 1.3m, Q3 2021 815.0k, Q4 2021 5.6m, Q1 2022 5.6m
28 HORIZON THERAPEUTICS PUB L SHS HZNP HZNP 465,000 $48.9m1.09% 1.09% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 465.0k
29 BRIDGEBIO PHARMA INC NOTE 2.500% 3/1 · principal BBIO 2.5 03.15.27 · principal BBIO 2.5 03.15.27 80,000,000 $47.4m1.06% 1.06% UnchangedPrincipal held: Q2 2021 80.0m, Q3 2021 80.0m, Q4 2021 80.0m, Q1 2022 80.0m
30 CENTENE CORP DEL COM CNC CNC 553,800 $46.6m1.04% 1.04% ReducedShares held: Q2 2021 995.0k, Q3 2021 1.0m, Q4 2021 1.0m, Q1 2022 553.8k -450.0k -450,000 -44.8%
31 GILEAD SCIENCES INC COM GILD GILD 765,489 $45.5m1.02% 1.02% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 765.5k
32 MOLINA HEALTHCARE INC COM MOH MOH 134,989 $45.0m1.01% 1.01% UnchangedShares held: Q2 2021 231.8k, Q3 2021 231.8k, Q4 2021 135.0k, Q1 2022 135.0k
33 AERIE PHARMACEUTICALS INC COM AERI AERI 4,695,020 $42.7m0.96% 0.96% UnchangedShares held: Q2 2021 825.9k, Q3 2021 3.0m, Q4 2021 4.7m, Q1 2022 4.7m
34 SEMA4 HOLDINGS CORP COM CL A SMFR SMFR 13,848,488 $42.5m0.95% 0.95% ReducedShares held: Q2 2021 0, Q3 2021 13.8m, Q4 2021 14.0m, Q1 2022 13.8m -118.3k -118,336 -0.8%
35 SINGULAR GENOMICS SYSTEMS IN COM COM 6,612,019 $41.7m0.93% 0.93% ReducedShares held: Q2 2021 9.1m, Q3 2021 9.1m, Q4 2021 9.1m, Q1 2022 6.6m -2.5m -2,500,000 -27.4%
36 ALPHATEC HLDGS INC COM NEW ATEC ATEC 3,594,829 $41.3m0.92% 0.92% UnchangedShares held: Q2 2021 3.4m, Q3 2021 3.6m, Q4 2021 3.6m, Q1 2022 3.6m
37 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 3,933,137 $38.2m0.85% 0.85% UnchangedShares held: Q2 2021 3.9m, Q3 2021 3.9m, Q4 2021 3.9m, Q1 2022 3.9m
38 BROOKDALE SR LIVING INC COM BKD BKD 5,379,000 $37.9m0.85% 0.85% AddedShares held: Q2 2021 3.3m, Q3 2021 5.3m, Q4 2021 4.3m, Q1 2022 5.4m +1.1m +1,104,192 25.8%
39 CYTOKINETICS INC COM NEW CYTK CYTK 952,703 $35.1m0.78% 0.78% AddedShares held: Q2 2021 1.2m, Q3 2021 1.5m, Q4 2021 809.0k, Q1 2022 952.7k +143.7k +143,703 17.8%
40 1LIFE HEALTHCARE INC NOTE 3.000% 6/1 · principal ONEM 3 06.15.25 · principal ONEM 3 06.15.25 40,000,000 $34.7m0.78% 0.78% NewPrincipal held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 40.0m
41 THE ONCOLOGY INSTITUTE INC COM STLN STLN 3,296,107 $32.1m0.72% 0.72% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 3.3m, Q1 2022 3.3m
42 PHARVARIS N V COM PHVS PHVS 1,577,078 $28.6m0.64% 0.64% ReducedShares held: Q2 2021 1.0m, Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m -4.3k -4,253 -0.3%
43 NOVAVAX INC NOTE 3.750% 2/0 · principal NVAX 3.75 02.01.23 · principal NVAX 3.75 02.01.23 25,000,000 $26.8m0.60% 0.60% UnchangedPrincipal held: Q2 2021 25.0m, Q3 2021 25.0m, Q4 2021 25.0m, Q1 2022 25.0m
44 BELLUS HEALTH INC NEW COM NEW BLU BLU 3,672,808 $25.3m0.57% 0.57% AddedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 2.4m, Q1 2022 3.7m +1.2m +1,223,808 50.0%
45 LARIMAR THERAPEUTICS INC COM LRMR LRMR 5,830,249 $23.6m0.53% 0.53% UnchangedShares held: Q2 2021 5.8m, Q3 2021 5.8m, Q4 2021 5.8m, Q1 2022 5.8m
46 REVOLUTION MEDICINES INC COM RVMD RVMD 891,587 $22.7m0.51% 0.51% UnchangedShares held: Q2 2021 1.6m, Q3 2021 1.6m, Q4 2021 891.6k, Q1 2022 891.6k
47 MIRATI THERAPEUTICS INC COM MRTX MRTX 270,000 $22.2m0.50% 0.50% AddedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 88.0k, Q1 2022 270.0k +182.0k +182,000 206.8%
48 GLAUKOS CORP COM GKOS GKOS 369,514 $21.4m0.48% 0.48% ReducedShares held: Q2 2021 0, Q3 2021 619.0k, Q4 2021 1.2m, Q1 2022 369.5k -791.9k -791,900 -68.2%
49 XERIS PHARMACEUTICALS INC NOTE 5.000% 7/1 · principal XERS 5 07.15.25 · principal XERS 5 07.15.25 18,000,000 $21.1m0.47% 0.47% UnchangedPrincipal held: Q2 2021 18.0m, Q3 2021 18.0m, Q4 2021 18.0m, Q1 2022 18.0m
50 DAY ONE BIOPHARMACEUTICALS I COM COM 2,086,449 $20.7m0.46% 0.46% ReducedShares held: Q2 2021 819.0k, Q3 2021 1.7m, Q4 2021 2.2m, Q1 2022 2.1m -116.1k -116,084 -5.3%
51 GOODRX HLDGS INC COM CL A GDRX GDRX 979,106 $18.9m0.42% 0.42% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 979.1k
52 NUVATION BIO INC COM CL A NUVB NUVB 3,577,233 $18.8m0.42% 0.42% UnchangedShares held: Q2 2021 3.6m, Q3 2021 3.6m, Q4 2021 3.6m, Q1 2022 3.6m
53 OUTSET MED INC COM OM OM 400,622 $18.2m0.41% 0.41% UnchangedShares held: Q2 2021 400.6k, Q3 2021 400.6k, Q4 2021 400.6k, Q1 2022 400.6k
54 HEALTH CATALYST INC NOTE 2.500% 4/1 · principal HCAT 2.5 04.15.25 · principal HCAT 2.5 04.15.25 15,000,000 $17.2m0.38% 0.38% UnchangedPrincipal held: Q2 2021 15.0m, Q3 2021 15.0m, Q4 2021 15.0m, Q1 2022 15.0m
55 IMMUNOGEN INC COM IMGN IMGN 3,470,675 $16.5m0.37% 0.37% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 3.5m
56 BIOCRYST PHARMACEUTICALS INC COM BCRX BCRX 1,012,000 $16.5m0.37% 0.37% ReducedShares held: Q2 2021 2.8m, Q3 2021 234.6k, Q4 2021 1.7m, Q1 2022 1.0m -674.1k -674,140 -40.0%
57 DA32 LIFE SCNCE TEC ACQSTN C CLASS A COM CLASS A COM 1,600,000 $15.5m0.35% 0.35% UnchangedShares held: Q2 2021 0, Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m
58 PROFOUND MED CORP COM NEW PROF PROF 1,713,797 $15.4m0.35% 0.35% UnchangedShares held: Q2 2021 1.3m, Q3 2021 1.3m, Q4 2021 1.7m, Q1 2022 1.7m
59 PTC THERAPEUTICS INC NOTE 3.000% 8/1 · principal PTCT 3 08.15.22 · principal PTCT 3 08.15.22 14,527,000 $15.1m0.34% 0.34% UnchangedPrincipal held: Q2 2021 14.5m, Q3 2021 14.5m, Q4 2021 14.5m, Q1 2022 14.5m
60 ALECTOR INC COM ALEC ALEC 1,055,192 $15.0m0.34% 0.34% UnchangedShares held: Q2 2021 1.1m, Q3 2021 1.1m, Q4 2021 1.1m, Q1 2022 1.1m
61 XILIO THERAPEUTICS INC COM COM 2,078,692 $14.7m0.33% 0.33% ReducedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 2.2m, Q1 2022 2.1m -75.4k -75,369 -3.5%
62 OAK STR HEALTH INC NOTE 3/1 · principal OSH 0 03.15.26 · principal OSH 0 03.15.26 18,000,000 $14.3m0.32% 0.32% NewPrincipal held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 18.0m
63 SPRINGWORKS THERAPEUTICS INC COM SWTX SWTX 249,988 $14.1m0.32% 0.32% ReducedShares held: Q2 2021 558.6k, Q3 2021 510.7k, Q4 2021 452.0k, Q1 2022 250.0k -202.0k -202,012 -44.7%
64 EVOLUS INC COM EOLS EOLS 1,229,234 $13.8m0.31% 0.31% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 1.2m
65 KALVISTA PHARMACEUTICALS INC COM KALV KALV 830,472 $12.2m0.27% 0.27% ReducedShares held: Q2 2021 2.2m, Q3 2021 2.2m, Q4 2021 1.2m, Q1 2022 830.5k -344.7k -344,659 -29.3%
66 COGENT BIOSCIENCES INC COM COGT COGT 1,601,000 $12.0m0.27% 0.27% UnchangedShares held: Q2 2021 1.6m, Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m
67 MERUS N V COM MRUS MRUS 437,000 $11.6m0.26% 0.26% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 437.0k, Q1 2022 437.0k
68 KINNATE BIOPHARMA INC COM KNTE KNTE 985,568 $11.1m0.25% 0.25% UnchangedShares held: Q2 2021 1.0m, Q3 2021 1.0m, Q4 2021 985.6k, Q1 2022 985.6k
69 APOLLO ENDOSURGERY INC COM COM 1,750,000 $10.6m0.24% 0.24% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 1.8m, Q1 2022 1.8m
70 SARISSA CAPITAL ACQUISITN CO CL A CL A 999,999 $9.9m0.22% 0.22% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 1,000.0k, Q1 2022 1,000.0k
71 EUCRATES BIOMEDICAL ACQU COR SHS SHS 999,999 $9.8m0.22% 0.22% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 1,000.0k, Q1 2022 1,000.0k
72 SENIOR CONNECT ACQUISITN COR COM CL A COM CL A 1,000,000 $9.8m0.22% 0.22% UnchangedShares held: Q2 2021 0, Q3 2021 1.0m, Q4 2021 1.0m, Q1 2022 1.0m
73 REVOLUTION HEALTHCAR AQ CORP CLASS A COM CLASS A COM 1,000,000 $9.8m0.22% 0.22% UnchangedShares held: Q2 2021 0, Q3 2021 1.0m, Q4 2021 1.0m, Q1 2022 1.0m
74 MEDTECH ACQUISITION CORP COM CL A COM CL A 999,999 $9.8m0.22% 0.22% UnchangedShares held: Q2 2021 0, Q3 2021 1,000.0k, Q4 2021 1,000.0k, Q1 2022 1,000.0k
75 INOZYME PHARMA INC COM COM 2,344,786 $9.6m0.21% 0.21% UnchangedShares held: Q2 2021 2.2m, Q3 2021 2.3m, Q4 2021 2.3m, Q1 2022 2.3m
76 AN2 THERAPEUTICS INC COM ANTX ANTX 584,136 $8.8m0.20% 0.20% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 584.1k
77 NYXOAH S A SHS NYXH NYXH 455,262 $8.7m0.19% 0.19% UnchangedShares held: Q2 2021 0, Q3 2021 300.8k, Q4 2021 455.3k, Q1 2022 455.3k
78 TURMERIC ACQUISITION CORP CL A CL A 750,000 $7.4m0.17% 0.17% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 750.0k, Q1 2022 750.0k
79 INSMED INC COM PAR $.01 INSM INSM 304,572 $7.2m0.16% 0.16% NewShares held: Q2 2021 200.0k, Q3 2021 0, Q4 2021 0, Q1 2022 304.6k
80 IGNYTE ACQUISITION CORP COM COM 725,000 $7.1m0.16% 0.16% UnchangedShares held: Q2 2021 0, Q3 2021 725.0k, Q4 2021 725.0k, Q1 2022 725.0k
81 TERNS PHARMACEUTICALS INC COM COM 2,345,959 $7.0m0.16% 0.16% UnchangedShares held: Q2 2021 2.3m, Q3 2021 2.3m, Q4 2021 2.3m, Q1 2022 2.3m
82 QUANTUM SI INC COM CL A QSI QSI 1,400,000 $6.6m0.15% 0.15% UnchangedShares held: Q2 2021 1.4m, Q3 2021 1.4m, Q4 2021 1.4m, Q1 2022 1.4m
83 GRAYBUG VISION INC COM SHS COM SHS 5,281,713 $6.5m0.15% 0.15% UnchangedShares held: Q2 2021 5.3m, Q3 2021 5.3m, Q4 2021 5.3m, Q1 2022 5.3m
84 BENEFITFOCUS INC NOTE 1.250%12/1 BNFT 1.25 12.15.23 BNFT 1.25 12.15.23 6,500,000 $6.3m0.14% 0.14% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 6.5m, Q1 2022 6.5m
85 ONCORUS INC COM COM 3,148,977 $5.6m0.13% 0.13% UnchangedShares held: Q2 2021 3.1m, Q3 2021 3.1m, Q4 2021 3.1m, Q1 2022 3.1m
86 VINCERX PHARMA INC COM NEW COM NEW 1,379,310 $5.5m0.12% 0.12% UnchangedShares held: Q2 2021 0, Q3 2021 1.4m, Q4 2021 1.4m, Q1 2022 1.4m
87 ORCHARD THERAPEUTICS PLC ADS ORTX ORTX 6,949,416 $4.9m0.11% 0.11% UnchangedShares held: Q2 2021 6.9m, Q3 2021 6.9m, Q4 2021 6.9m, Q1 2022 6.9m
88 ORION ACQUISITION CORP COM CL A COM CL A 500,000 $4.9m0.11% 0.11% UnchangedShares held: Q2 2021 0, Q3 2021 500.0k, Q4 2021 500.0k, Q1 2022 500.0k
89 WEREWOLF THERAPEUTICS INC COM HOWL HOWL 958,125 $4.2m0.09% 0.09% UnchangedShares held: Q2 2021 2.6m, Q3 2021 1.8m, Q4 2021 958.1k, Q1 2022 958.1k
90 CULLINAN THERAPEUTICS INC COM CGEM CGEM 375,585 $3.9m0.09% 0.09% ReducedShares held: Q2 2021 1.0m, Q3 2021 1.0m, Q4 2021 671.7k, Q1 2022 375.6k -296.1k -296,105 -44.1%
91 ACUTUS MED INC COM AFIB AFIB 2,648,386 $3.7m0.08% 0.08% UnchangedShares held: Q2 2021 4.3m, Q3 2021 2.6m, Q4 2021 2.6m, Q1 2022 2.6m
92 FOGHORN THERAPEUTICS INC COM FHTX FHTX 238,865 $3.6m0.08% 0.08% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 238.9k
93 RHYTHM PHARMACEUTICALS INC COM RYTM RYTM 291,005 $3.4m0.07% 0.07% ReducedShares held: Q2 2021 2.0m, Q3 2021 2.0m, Q4 2021 1.9m, Q1 2022 291.0k -1.6m -1,576,462 -84.4%
94 DELCATH SYS INC COM NEW DCTH DCTH 500,000 $3.2m0.07% 0.07% UnchangedShares held: Q2 2021 500.0k, Q3 2021 500.0k, Q4 2021 500.0k, Q1 2022 500.0k
95 NEOGENOMICS INC NOTE 0.250% 1/1 · principal NEO 0.25 01.15.28 · principal NEO 0.25 01.15.28 2,500,000 $1.7m0.04% 0.04% UnchangedPrincipal held: Q2 2021 2.5m, Q3 2021 2.5m, Q4 2021 2.5m, Q1 2022 2.5m
96 AMERICAN WELL CORP CL A CL A 391,115 $1.6m0.04% 0.04% ReducedShares held: Q2 2021 991.1k, Q3 2021 991.1k, Q4 2021 991.1k, Q1 2022 391.1k -600.0k -600,000 -60.5%
97 ANNEXON INC COM ANNX ANNX 583,913 $1.6m0.04% 0.04% UnchangedShares held: Q2 2021 583.9k, Q3 2021 583.9k, Q4 2021 583.9k, Q1 2022 583.9k
98 BIOATLA INC COM BCAB BCAB 289,002 $1.4m0.03% 0.03% UnchangedShares held: Q2 2021 245.4k, Q3 2021 464.3k, Q4 2021 289.0k, Q1 2022 289.0k
99 THE ONCOLOGY INSTITUTE INC *W EXP 11/15/202 STLNW STLNW 1,250,000 $1.4m0.03% 0.03% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 1.2m, Q1 2022 1.2m
100 CAREMAX INC *W EXP 06/08/202 *W EXP 06/08/202 672,000 $1.3m0.03% 0.03% UnchangedShares held: Q2 2021 672.0k, Q3 2021 672.0k, Q4 2021 672.0k, Q1 2022 672.0k

Sold out since Q4 2021

SecurityTickerShares held beforeValue then
APRIA INC 1,655,795 $54.0m1.7m shares
PROTAGONIST THERAPEUTICS INC PTGX PTGX 1,172,943 $40.1m1.2m shares
PACIRA BIOSCIENCES INC PCRX PCRX 596,338 $35.9m596.3k shares
ESPERION THERAPEUTICS INC NE ESPR ESPR 5,000,000 $25.0m5.0m shares
MERIDIAN BIOSCIENCE INC VIVO VIVO 1,125,083 $23.0m1.1m shares
FIGS INC FIGS FIGS 829,707 $22.9m829.7k shares
NEVRO CORP NVRO NVRO 216,000 $17.5m216.0k shares
APELLIS PHARMACEUTICALS INC APLS APLS 343,213 $16.2m343.2k shares
SAREPTA THERAPEUTICS INC SRPT SRPT 141,000 $12.7m141.0k shares
BLUEPRINT MEDICINES CORP BPMC BPMC 110,000 $11.8m110.0k shares
LIANBIO LIANY LIANY 1,782,747 $11.0m1.8m shares
WEAVE COMMUNICATIONS INC WEAV WEAV 554,519 $8.4m554.5k shares
GUARDANT HEALTH INC GH 0 11.15.27 GH 0 11.15.27 8,000,000 $8.1m8.0m shares
PRIVIA HEALTH GROUP INC PRVA PRVA 300,000 $7.8m300.0k shares
HYPERFINE INC HYPR HYPR 1,000,000 $7.2m1.0m shares
DEFINITIVE HEALTHCARE CORP DH DH 250,000 $6.8m250.0k shares
PYXIS ONCOLOGY INC PYXS PYXS 311,754 $3.4m311.8k shares
WAVE LIFE SCIENCES LTD 96663EUR 96663EUR 552,690 $1.7m552.7k shares
BIODELIVERY SCIENCES INTL IN BDSI BDSI 29,204 $91.0k29.2k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
GLAUKOS CORP GKOS · Call GKOSCall 45,200 $2.6m45.2k shares Unchanged